Vertex Pharmaceuticals announced positive Phase 2b AMPLIFIED trial results for inaxaplin, its experimental treatment for APOL1-mediated kidney disease. In the 41-patient study, a 45 mg daily dose reduced urine albumin to creatinine ratios by 42.7% in patients with modest proteinuria and 17.3% in those with type 2 diabetes. The drug was well tolerated with mild or moderate adverse events. Vertex has completed enrollment for its Phase 2/3 AMPLITUDE trial, with interim data expected in early 2027.
Efficacy and design of Phase 2b AMPLIFIED study
- ▪In the first cohort of the Phase 2b AMPLIFIED study, a 45 mg dose of inaxaplin led to a 42.7% reduction in urine albumin to creatinine ratio and a 44.7% decrease in urine protein to creatinine ratio at week 13.
- ▪The Phase 2b AMPLIFIED study was a single-arm, open-label trial evaluating inaxaplin over 13 weeks in two cohorts of APOL1-mediated kidney disease patients: 23 with modest proteinuria, and 18 with type 2 diabetes.
- ▪Vertex Pharmaceuticals announced positive results on September 22, 2026, from its Phase 2b AMPLIFIED study evaluating a 45 mg once-daily dose of inaxaplin in 41 patients.
Safety of inaxaplin in Phase 2b AMPLIFIED study
- ▪The most common adverse event in the Phase 2b AMPLIFIED study was headache, occurring in 7.3% of subjects, while five patients experienced isolated, asymptomatic transaminase elevations that resolved.
- ▪Inaxaplin was generally safe and well tolerated in the Phase 2b AMPLIFIED study, with no serious drug-related adverse events and all adverse events being mild or moderate in severity.
Phase 2/3 AMPLITUDE trial of inaxaplin
- ▪Vertex Pharmaceuticals completed enrollment in the Phase 2/3 AMPLITUDE trial of inaxaplin, with plans to share data from a pre-planned interim analysis in early 2027.
- ▪Positive interim data from the Phase 2/3 AMPLITUDE trial, which evaluates a 45 mg once-daily oral dose of inaxaplin against placebo, could support accelerated approval in the United States.
Analyst ratings on Vertex Pharmaceuticals
- ▪Barclays analyst Eliana Merle issued a Buy rating on Vertex Pharmaceuticals on September 25, 2026, while Canaccord Genuity maintained a Hold rating on the stock.
- ▪BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals on September 25, 2026, setting a price target of $600.00.
Background on APOL1-mediated kidney disease
- ▪There are currently no approved therapies available to treat patients with APOL1-mediated kidney disease.
- ▪APOL1-mediated kidney disease is a rapidly progressing, proteinuric kidney disease caused by two variants in the APOL1 gene, affecting approximately 150,000 people of African ancestry in the United States and Europe.
Debatable claims
- ▪Vertex's Phase 2b trial design limits the conclusiveness of its inaxaplin efficacy data
- ▪The FDA should grant accelerated approval to Vertex's inaxaplin based on interim trial data
Story comments
Loading comments…